Kornimate/medical-research-clean huggingface dataset:
mobile cognitive behavioral therapy for medical and graduate students

Conditions: Anxiety Disorders; Depression

Summary: the study aims to assess and compare clinician-delivered cognitive behavior therapy (cbt) supplemented with "maya", a mobile cognitive behavioral therapy app program to clinician-delivered cognitive behavioral therapy alone. the experimental group will be asked to use the mobile application at least two times per week for six weeks, for at least 20 minutes on each of the two days in addition to the clinician-delivered cbt. participants will complete a weekly self-report assessment battery designed to assess anxiety and mood symptoms. the investigators think that clinician-delivered cbt supplemented with "maya" will improve more effective at improving symptoms of anxiety and depression than clinician-delivered cbt alone.

growing evidence suggests a need for anxiety and depression treatments that can be disseminated easily to young adults. many do not seek out treatment for reasons including lack of availability and high cost. there is a growing need for accessible, affordable, research-supported treatments designed to increase the practice of skills and therefore improve treatment outcomes. graduate students use mobile devices frequently; thus, mobile app-based interventions may be particularly appealing to individuals in this age range with anxiety or depression who are unable to access more traditional psychotherapy administered in person by a therapist. the study aims to compare the efficacy and feasibility of clinician-delivered cognitive behavior therapy supplemented with the mobile app program to clinician- delivered cognitive behavioral therapy alone. young adults with anxiety and/or depression will be randomized to clinician-delivered cbt (active control group) or to the clinician cbt + mobile app (intervention group). in the active control group, participants will participate in weekly clinician-delivered cognitive behavior therapy. in the intervention group, participants will participate in weekly clinician-delivered cognitive behavior therapy and use a mobile application for at least 20 minutes two times per week for six weeks.

Eligibility criteria:
inclusion criteria: * age between 18 and 40 years. * clinically significant anxiety (as determined by a score of 10 or greater on the gad-7) or clinically significant depression (as determined by a score of 10 or greater on the phq-9). * current graduate student at weill cornell medicine. * access to an apple iphone exclusion criteria: * lifetime diagnosis of a bipolar or psychotic disorder. * intent or plan to attempt suicide.

Keywords: anxiety mobile application cognitive behavioral therapy graduate students
genetic markers and proliferative diabetic retinopathy

Conditions: Proliferative Diabetic Retinopathy

Summary: type 2 diabetes (td2) is the leading cause of new cases of preventable blindness in these countries (and the gold-standard treatment, laser photocoagulation has proven to be effective in preventing vision loss at the end stage of eye disease due to proliferative diabetic retinopathy (pdr) that occurs in 3 to 6 % of the cases.therefore, the ongoing search for predictive factors of sight threatening stages of diabetic retinopathy has become more important. previous studies that have examined candidate predictive factors for diabetic eye disease have mostly focused on systemic risk factors leading to pdr. among various clinical parameters, increased hba1c % levels, uncontrolled blood pressure, diabetes duration, neuropathy and elevated triglycerides have been associated with pdr. some genetic factors may also account for the development of pdr and are prospectively considered in this study .

in a previous study (2011), investigators demonstrated a statistically significant relation between the endothelial lipase(el) c.584c\>t polymorphism and the occurrence of diabetic retinopathy in 396 french patients with diabetes type 2 (dt2) with a longitudinal follow-up. secondly (2014) in a subgroup of 287 dt2 patients, investigators showed the impact of the el rare t allele was consistent with a recessive mode of inheritance, with homozygotes for the rare allele differing from the carriers of the major allele. importantly, the homozygotes for the rare t allele were more likely to present with advanced stages of diabetic retinopathy (severe non proliferative and proliferative disease) and particularly with proliferative diabetic retinopathy (pdr). based on this model investigators decided to conduct a case-control prospective study comparing 155 french patients with dt2 with pdr (cases) and 155 french patients with dt2 without pdr (controls) on the basis of two genetic parameters: el c.584c\>t polymorphism that investigators previously studied and the c(-106)t aldose reductase polymorphism widely studied in diabetic retinopathy.

Eligibility criteria:
inclusion criteria: * type 2 diabetic patients * patient with proliferative diabetic retinopathy (for arm 1) * patient with non proliferative diabetic retinopathy (for arm 2) * patient older than 18 years * patient consenting to participate to the study * patient enrolled in the national healthcare insurance program
effects of lumbar transcutaneous electrical nerve stimulation on exercise performance in patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease is a leading cause of morbidity and mortality worldwide. pulmonary rehabilitation effectively improves outcomes in patients with chronic respiratory disease. there is a link between training intensity and physiological improvements following pulmonary rehabilitation. however, high intensity training is not sustainable for every patients. therefore, actual strategies for pulmonary rehabilitation aimed at decreasing dyspnea to improve muscle work. electrical muscle stimulation is widely used during rehabilitation to promote muscle function recovery. transcutaneous electrical nerve stimulation was recently used to relief dyspnea and improve pulmonary function in patients with chronic respiratory disease. moreover, spinal anesthesia with fentanyl has been shown to be effective in improving exercise tolerance in patients with chronic obstructive pulmonary disease (inhibiting group iii and iv muscle afferents). as transcutaneous electrical muscle stimulation stimulates the same receptors in the spinal cord dorsal horn as fentanyl, it is hypothesized that it could also improve exercise capacity. therefore, the aim of this study is to assess wether transcutaneous electrical stimulation (high or low frequency) is effective in improving exercise capacity in patients with severe to very severe chronic obstructive pulmonary disease.

design : cross-over. patients will perform three constant workload testing (cwt) on different days under three different conditions. the intervention during the tests will be randomly assigned (concealed allocation) : * sham transcutaneous electrical nerve stimulation ; * high-frequency transcutaneous electrical nerve stimulation ; * low-frequency transcutaneous electrical nerve stimulation.

Eligibility criteria:
inclusion criteria: * age \> 18 years; * chronic obstructive pulmonary disease gold iii-iv; * eligible for pulmonary rehabilitation; * never used electrical stimulation. non-inclusion criteria: * pregnant woman or likely to be; * patient under guardianship; * history of epilepsy, heart pace-maker or defibrillator, inguinal or abdominal hernia; * recent lumbar surgery or skin lesion; * allergy to surface electrodes; * lumbar sensitivity impairment; * opiate treatment during the last 3 months. exclusion criteria: * acute exacerbation of chronic obstructive pulmonary disease
new criteria for accessory pathway localization from surface ecg

Conditions: Accessory Pathway

Summary: study for discovering new criteria for localization of site of accessory pathway from surface ecg

the study aims for discovering new criteria for percise localization of accessory pathway from surface ecg in referance to final flouroscopic ablation site

Eligibility criteria:
inclusion criteria: * any patient with manifest accessory pathway . exclusion criteria: * multiple accessory pathways .previous ablation.
exercise and disease progression in amyotrophic lateral sclerosis patients

Conditions: Amyotrophic Lateral Sclerosis

Summary: this study evaluated the influence of a tailored aerobic exercise protocol on the functional outcome in als patients. in addition, the investigators compare some cpet variables collected during exercise testing in both groups.

this work aimed to evaluate the effects of a moderate aerobic exercise with controlled intensity determined by cardiopulmonary exercise testing (cpet) and its role on the functional status in als patients versus standard care. additionally, the investigators explored the performance of cpet variables - oxygen uptake (vo2) expressed in l/min, in percentage of predicted or in metabolic equivalents (mets) at peak effort, at anaerobic threshold (at), the respiratory compensation point (rcp) when achieved, dioxide carbon output in l/min (vco2) and the minute ventilation in l/min (ve) throughout the study. assessments:(diagnostic visit - t0), at study entry (t1) and 6 months after (t2) using: functional status by amyotrophic lateral sclerosis functional rating scale-revised (alsfrs-r), respiratory function tests (rft): forced vital capacity predicted (%fvc) and oxygen saturation provided by pulse oximetry. cpet was performed in both groups at study entry and 6 months later (t1 and t2), using a treadmill (woodway®) coupled with a gas exchange analyzer (metalyzer® 3b) with ergo-spirometry system using a breath-by-breath technology developed by cortex® systems. intervention: g1(interventional group) performed moderate exercise protocol two times/week in a treadmill in the lower range of the training zone determined by cpet + standard care (range of motion exercise, gait and balance training under continuous pulse oximetry observation). g2 (control group) performed a standard care exercise program at home or at other rehabilitation units without pulse oximetry observation.

Eligibility criteria:
inclusion criteria: * consecutive patients diagnosed with definite, probable, or probable laboratory supported als * disease duration from first symptoms between 6-24 months to exclude slow and fast progression * alsfrs-r ≥ 30 * fvc (%predicted) ≥ 70% exclusion criteria: * other medical conditions, like cardiac insufficiency and lung disorders or others conditions limiting exercise training; * heavy smoking habits with laboratorial evidence of significant bronchial constriction; * signs of associated dementia or psychiatric disorders. note: none of the patients were on tube feeding, invasive or non-invasive mechanical ventilation at admission of study protocol (t1).

Keywords: amyotrophic lateral sclerosis aerobic exercise functional outcome non-invasive ventilation oxygen uptake
cosmic study - comparing open scarf/akin osteotomy and minimally invasive chevron/akin. a feasibility study

Conditions: Hallux Valgus

Summary: the aim of this study is to assess the feasibility of conducting a study to compare the patient recorded and clinical outcomes for the surgical management of hallux valgus correction. a prospective trial will randomise the patients into two groups - open scarf/akin osteotomy and minimally invasive chevron/akin osteotomy.

this study will assess the feasibility of a prospective trial that would randomise the patients into two groups for surgical correction of hallux valgus - open scarf/akin osteotomy and minimally invasive chevron/akin osteotomy. patients will complete a validated questionnaire (manchester oxford foot questionnaire) preoperatively and post operatively at 6 months and 1 year. range of motion of the great toe metatarsal phalangeal joint will also be measured by goniometer. this study will assess the ability to recruit and retain patients and thus determine if a study comparing the surgical techniques would be feasible. in addition, for data collected statistical differences of the change in patient reported outcomes, range of motion between the two groups will be calculated with a significance level of p\<0.05. this study will assess if a larger study comparing minimally invasive to open hallux valgus correction would be able to be performed

Eligibility criteria:
inclusion criteria: * patients over 18 years of age. * patients with hallux valgus deformity suitable for treatment by both open scarf/akin and mica procedures. * patients with no significant co-morbidities that would increase their risk of procedure. * patients able to understand and complete questionnaires. * patients with the capacity to provide informed consent. * patients who have, in addition to hallux valgus deformity, lesser toe deformities requiring correction distal to the metatarsal phalangeal joint at time of procedure. * patients without significant other mid foot or hind foot pathology exclusion criteria: * patients under 18 years of age * patients with severity of hallux valgus deformity necessitating open procedure * patients with significant co-morbidities that would increase the risk of surgery * patients unable to understand or complete questionnaires. * patients without the capacity to provide informed consent. * patients with additional deformity requiring additional procedures proximal to the metatarsal phalangeal joint.
role of octreotide in preventing pancreatic fistula after pancreaticoduodenectomy (pd) in patients with soft pancreas

Conditions: Pancreatic Fistula

Summary: this randomized controlled trial (rct) aims at assessing the influence of octreotide on pancreatic fistula or complications following pancreatoduodenectomy in patients with soft pancreas. previously reported trials have included all types of pancreatic resections and have include all types of pancreas and have shown no clearcut benefit of octreotide after pancreaticoduodenectomy (pd). soft pancreas and normal sized duct are the risk factors for fistula following pd. this study's focus is on this select group of patients and aims to assess the role of octreotide in patients with soft pancreas.

study design: prospective open labeled randomized trial. aim: study aims at assessing the influence of octreotide on pancreatic fistula or complications following pancreatoduodenectomy in patients with soft pancreas.

Eligibility criteria:
inclusion criteria:elective surgery patients undergoing pancreatoduodenectomy * soft pancreas, no dilated duct exclusion criteria: * age \> 75 years old * documented chronic pancreatitis * previous pancreatic surgery * previous gastric surgery vagotomy * documented pancreatic duct dilatation

Keywords: octreotide pancreatic fistula soft pancreas pancreatoduodenectomy
the effects of trunk impairment on fatigue and balance

Conditions: Cerebral Palsy

Summary: fatigue is a common symptom associated with cerebral palsy (cp); it has been estimated that up to 40% of adolescents with cp experience fatigue that impacts their quality of life and daily activities. although fatigue was stated as the primary symptom, a limited number of studies were found on secondary motor and nonmotor symptoms related to trunk control in children when the literature was examined.


Eligibility criteria:
inclusion criteria: aged between 2-18 years old; (2) had a form of cp; (3) had the cognitive competence to participate to the all assessments. exclusion criteria: the sufferers who had an additional neurological or musculoskeletal disability, unstable medical conditions, any recent medical intervention (such as tendon lengthening surgery or botulinum toxin injection...) were excluded
validation of the gids and description of phosphate disorders

Conditions: Organ Dysfunction Scores; Hypophosphatemia

Summary: this study will address two specific research questions simultaneously: 1. validation of the gastrointestinal (gi) dysfunction score (gids). 2. description of epidemiology, risk factors, and management of phosphate disorders. the aim is to recruit 20 icus and 1500 icu patients. sites will recruit all consecutive adult patients to a maximum of 120 patients or a maximum recruitment period of 8 weeks, whichever comes first. daily data collection on gastrointestinal signs and symptoms as well as phosphate values and management will be collected during icu stay for maximum of 7 days. 28 and 90 day mortality and days free of organ support will be the main outcomes. secondary outcomes include prevalence of hypo- and hyperphosphatemia and description of their management.

patient population all consecutive adult patients that are admitted to participating icu during a recruitment period of maximum 8 weeks. duration of the study for the individual patient: 1. study period of a maximum of 7 days 2. follow-up period of a maximum of 90 days all patients will be included in the part a of the study validating gids, patients from sites with routine serum phosphate measurements will be included also in the part b of the study where additional data on serum phosphate levels and management of phosphate disorders will be collected. there will be no additional measurements due to study participation, daily routine is documented. baseline characteristics will be collected at icu admission/study inclusion daily data include routine data on organ dysfunctions and organ support therapies and specific data on phosphate where available. outcome data include 28 and 90 days mortality, and days free of organ support by day 28.

Eligibility criteria:
inclusion criteria: * admission to icu during the study period * age ≥18 years exclusion criteria: * age \<18 years; * patients with restrictions of care such as "no intubation" or "no renal replacement therapy" on icu admission and patients admitted for treatment as organ donors; * continuous chronic home ventilation for neuromuscular disease; * declined participation or informed consent (if the local ethics committee requests the latter for this non-interventional study); * readmission to icu during the study period
glycosylation analysis of lupus anti-dna antibodies (gala)

Conditions: Lupus Erythematosus Disseminatus; Autoimmune Diseases; Chronic Disease

Summary: systemic lupus erythematosus (sle) is a severe autoimmune disease in which patients often develop numerous autoantibodies (abs). unfortunately, none of the sle specific abs described so far (anti-dna, -c1q, -nucleosome) are correlated enough to the disease activity to be used as a useful biomarker and reliably help in the therapeutic decision. abs effector functions, including antibody-dependent cell-mediated cytotoxicity (adcc), antibody-dependent cellular phagocytosis (adcp) and antibody-mediated complement activation, are conditioned by the structure of the crystallizable fragment (fc) and especially the n-linked oligosaccharide structures attached to the asparagine-297 in the ch2 domain of the fc region. it has been shown that the decrease in galactosylation, sialylation and fucolylation is generally associated with inflammatory function of circulating igg whereas abs with sialic acid, fucose and/or galactose in asn-297 are anti-inflammatory. this major role of ab glycosylation in the regulation of the effector and pathogenic functions of abs have been well documented in rheumatoid arthritis and anca associated vasculitis with a good correlation between ab sialylation and disease activity. in lupus, it has been shown that glycosylation of total igg is also altered and correlated with disease activity but glycosylation analysis of the les specific abs is still lacking. the aim of this study is to analyse by mass spectrometry (ms) the different glycoforms of anti-dna abs in lupus patients and find a correlation with disease activity.

140 adult patients with lupus and anti-dna abs will be prospectively recruited in the university hospital of montpellier and nîmes (department of rheumatology, internal medicine and nephrology) and followed during 1 year. blood samples will be drawn at inclusion, at 1 year and during any flare of the disease. after centrifugation (2000g x 10 minutes) serum will be aliquoted and frozen at -80°c. at the end of the study, total igg will be isolated using protein g and anti-dna abs will be purified from total igg with dna affinity columns. glycosylation status of the anti-dna abs will be extensively determined by mass spectrometry and correlated to disease activity (sledai).

Eligibility criteria:
inclusion criteria: * patients presenting with led according to the acr/eular 2019 criteria, all clinical forms combined, quiescent or in flare with positive native anti-dna antibodies, providing oral informed consent. exclusion criteria: * patients under protection of justice or unable to receive a clear information. * high probability of non-compliance with the protocol or withdrawal during the study * already involved in another interventional clinical study

Keywords: lupus erythematosus autoantibody anti-dna antibody glycosylation
emd 273066 in patients with recurrent epcam positive ovarian, prostate, colorectal or non-small cell lung cancers when first given cyclophosphamide

Conditions: Ovarian Cancer; Colorectal Cancer; Carcinoma, Non-small-cell Lung; Prostate Cancer

Summary: this study is looking at the safety and tolerability of the experimental biological drug emd 273066 when given with low dose cyclophosphamide to patients with recurring epcam positive ovarian, prostate, colorectal or non-small cell lung cancers. emd 273066 is an experimental biological drug that may increase the immune response to certain cancers. patients will be enrolled in groups of 3, with each successive group receiving a higher dose if the prior group adequately tolerates the study medication.


Eligibility criteria:
inclusion criteria: * recurrent non-small cell lung, colorectal, ovarian or prostate cancer * no more than two lines of prior chemotherapy * positive epcam expression * karnofsky performance status \> 70% * adequate laboratory results * normal cardiac stress test exclusion criteria: * evidence of brain metastases * pregnant or lactating females * significant infection * prior receipt of emd 273066 * unable to interrupt anti-hypertensive medications 2 days prior to and through each cycle of study medication administration * uncontrolled hypertension * previous diagnosis of addison's disease * previous diagnosis of an autoimmune disease * organ transplant * insulin-dependent diabetes * history of acute pancreatitis * congestive heart failure

Keywords: epcam monoclonal-antibody targeted therapy colorectal prostate non-small cell lung cancer ovarian solid tumor